Stelara 90 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DR26FCRF8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $33,168
Award facts
- Contract value 100% obligated
- $33,168.26 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $33,168.26 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. This firm fixed-price delivery order, issued on November 3, 2025, with an ultimate completion date of November 25, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring pharmaceutical and medical supply needs across Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group holds contract SPE2DR under the PPV-G GEN V program, which was awarded on November 13, 2025, with a ceiling value of $499,999,999 and extends through December 31, 2036, inclusive of a 30-month base period and three optional 30-month renewal periods. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals, positioning it as a critical supplier within the federal military medical supply chain. This delivery order for Stelara, a biologic immunosuppressant, reflects the contractor's demonstrated capability to fulfill the specialized pharmaceutical requirements of the Department of Defense healthcare system globally.
Quick answers
Who was awarded contract SPE2DR26FCRF8?
SPE2DR26FCRF8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 3, 2025.
How much is contract SPE2DR26FCRF8 worth?
The government has obligated $33,168 on SPE2DR26FCRF8.
Is contract SPE2DR26FCRF8 an order under another contract?
Yes. SPE2DR26FCRF8 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRF8 competed?
The extent of competition for SPE2DR26FCRF8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award